Background Geranylgeranylacetone (GGA), an isoprenoid compound which includes retinoids, has been used orally as an anti-ulcer drug in Japan. GGA acts as a potent inducer of anti-viral gene expression by stimulating ISGF3 formation in human hepatoma cells. This drug has few side effects and reinforces the effect of IFN when administered in combination with peg-IFN and ribavirin. This study verified the anti-HCV activity of GGA in a replicon system. In addition, mechanisms of anti-HCV activity were examined in the replicon cells. Methods OR6 cells stably harboring the full-length genotype 1 replicon containing the Renilla luciferase gene, ORN/C-5B/KE, were used to examine the influence of the anti-HCV effect of GGA. After treatment, the cells were harvested with Renilla lysis reagent and then subjected to a luciferase assay according to the manufacturer's protocol. Result The results showed that GGA had anti-HCV activity. GGA induced anti-HCV replicon activity in a time-and dose-dependent manner. GGA did not activate the tyrosine 701 and serine 727 on STAT-1, and did not induce HSP-70 in OR6 cells. The anti-HCV effect depended on the GGA induced mTOR activity, not STAT-1 activity and PKR. An additive effect was observed with a combination of IFN and GGA. Conclusions GGA has mTOR dependent anti-HCV activity. There is a possibility that the GGA anti-HCV activity can be complimented by IFN. It will be necessary to examine the clinical effectiveness of the combination of GGA and IFN for HCV patients in the future.
Introduction
Currently, chronic hepatitis C virus (HCV) infection is the major cause of hepatocellular carcinoma worldwide [1] . Therefore, an anti-HCV strategy is important for prevention of carcinogenesis. The treatment of HCV with a combination of pegylated interferon (IFN) and ribavirin is effective in 80% of HCV genotype 2 or 3 cases, but less than 50% of genotype 1 cases. New anti-HCV agents have been developed to inhibit the life cycle of HCV and are used in combination with IFN-a to ameliorate the salvage rate of HCV infection [2] . It is necessary to improve the salvage rate of HCV infection by clarifying the efficacy of IFN treatment since IFN-a is the most basic agent for HCV treatment. Any agents that can support IFN activity will improve the therapeutic effect for HCV infected patients.
Geranylgeranylacetone (GGA), an isoprenoid compound, which includes retinoids, has been used orally as an anti-ulcer drug developed in Japan [3] . GGA protects the gastric mucosa from various types of stress without affecting gastric acid secretion [4, 5] . Moreover, GGA suppresses cell growth and induces differentiation or apoptosis in several human leukemia cells [6, 7] . Another isoprenoid compound, 3,7,11,15-tetramethyl-2,4,6,-10,14-hexadecapentaenoic acid, which is designated as an acyclic retinoid because it has the ability to interact with nuclear retinoid receptors [8] , causes apoptosis in certain human hepatoma cells [9] . GGA acts as a potent inducer of antiviral gene expression by stimulating the ISGF3 formation in human hepatoma cells [10] . GGA induces the expression of antiviral proteins such as 2 0 5 0 -oligoadenylate synthetase (2 0 5 0 -OAS) and double-stranded RNA-dependent protein kinase (PKR) in hepatoma cell lines. GGA stimulates 2 0 5 0 -OAS and PKR gene expression at the transcriptional level through the formation of interferon-stimulated gene factor 3 (ISGF-3), which regulates the transcription of both genes. GGA induces the expression of signal transducers and activators of transcription 1, 2 (STAT-1, STAT-2) and p48 proteins, components of ISGF3, together with the phosphorylation of STAT1 [10] . However, no anti-HCV activity was observed.
A cell culture HCV replicon system has been developed as a useful tool for the study of HCV replication and mass screening for anti-HCV reagents. OR6 cells stably harboring the full-length genotype 1 replicon containing the Renilla luciferase gene, ORN/C-5B/KE [11] , were used to examine the influence of the anti-HCV effect of IFN. The luciferase activity in cell lysate of OR6 was correlated with the HCV-RNA concentration, and the IC50 of IFN-a was less than 10 IU/mL [11] . The OR6 system is a useful and sensitive cell culture replicon system. This study verified the anti-HCV activity of GGA in the OR6 system. In addition, the mechanisms of anti-HCV activity were examined in OR6 cells.
Materials and methods

Reagents
GGA was a generous gift from Eisai Co. (Tokyo, Japan). Recombinant human IFN-a2a was purchased from Nippon Rosche Co. (Tokyo, Japan). Wortmannin, LY294002, Akt inhibitor and rapamycin were purchased from Calbiochem (La Jolla, CA, USA).
HCV replicon system OR6 cells stably harboring the full-length genotype 1 replicon, ORN/C-5B/KE, were used to examine the influence of the anti-HCV effect of GGA. The cells were cultured in Dulbecco's modified Eagle's medium (Gibco-BRL, Invitrogen) supplemented with 10% fatal bovine serum, penicillin and streptomycin and maintained in the presence of G418 (300 mg/L; Geneticin, Invitrogen). This replicon was derived from the 1B-2 strain (strain HCV-o, genotype 1b), in which the Renilla luciferase gene is introduced as a fusion protein with neomycin to facilitate the monitoring of HCV replication.
Reporter gene assay
The OR6 cells were grown in 24-well plates. One day later, the cells were incubated in the absence or presence of varying concentrations of chemical blockers and GGA. After treatment, the cells were harvested with Renilla lysis reagent (Promega, Madison, WI, USA) and luciferase activity in the cells was determined using a luciferase reporter assay system and a TD-20/20 luminometer. The data were expressed as the relative luciferase activity.
Western blotting and antibodies
Western blotting with anti-STAT-1, anti-PKR (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-tyrosine-701 phosphorylated STAT-1, anti-serine-727 phosphorylated STAT-1, anti-serine-2448 phosphorylated mTOR, antimTOR, anti-threonine-389 phosphorylated p70S6K, antip70S6K (Cell Signaling, Beverly, MA, USA) and anti-HSP70 (Stressmarq Biosciences Inc, Victoria, Canada) was performed as described previously [10] . Briefly, OR6 cells were lysed by the addition of a lysis buffer (50 mmol/L Tris-HCl, pH 7.4, 1% Np40, 0.25% sodium deoxycholate, 0.02% sodium azide, 0.1% SDS, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L PMSF, 1 mg/mL each of aprotinin, leupeptin and pepstatin, 1 mmol/L sodium o-vanadate and 1 mmol/L NaF). The samples were separated by electrophoresis on 8-12% SDS polyacrylamide gels and electrotransferred to nitrocellulose membranes, and then blotted with each antibody. The membranes were incubated with horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG, and the immunoreactive bands were visualized using the ECL chemiluminescence system (Amersham Life Science, Buckinghamshire, England). siRNA transfection assay mTOR gene knockdown was performed using siRNA (Cell Signaling, Beverly, MA, USA). OR6 cells were transfected with100 nmol/L mTOR specific and non-targeted siRNA as a control in accordance with the appended manual. One day later, the cells were incubated in either the absence or presence of 50 lmol/L GGA. mTOR kinase activity assay
The cells were washed two times with TBS and lysed by addition of lysis buffer [50 mM Tris HCl, pH 7.4, 100 mM NaCl, 50 mM b-glycerophosphate, 10% glycerol (w/v), 1% Tween-20 detergent (w/v), 1 mM EDTA, 20 nM microcystin-LR, 25 mM NaF, and a cocktail of protease inhibitors]. The insoluble materials were removed by centrifugation at 10,000 rpm for 15 min at 4°C, and the supernatants were collected and subjected to analysis of the mTOR kinase activity using a commercially available kit (Calbiochem, San Diego, USA) according to the manufacturer's instructions.
Results
GGA with or without IFN had anti-HCV activity OR6 cells, the full-length HCV replication system, were used to examine the effect of GGA. The cells were treated with 1-100 lmol/L of GGA for 24 h and the amount of HCV replicon was measured by the Renilla luciferase assay (Fig. 1a) . The relative Renilla luciferase activity decreased in a dose-dependent manner. Furthermore, GGA induced anti-HCV replicon activity was time dependent (Fig. 1b) . GGA was combined with IFN-a to examine the additive effect (Fig. 1c) . One or 10 lmol/L of GGA combined with IFN-a decreased the relative Renilla luciferase activity slightly (Fig. 1c ). However, 50 or 100 lmol/L of GGA combined with IFN-a decreased the relative Renilla luciferase activity with statistical difference. GGA treatment did not have any statistically significant effect on cell viability from 1 to 100 lmol/L of GGA for 24 h (data not shown).
GGA did not activate the tyrosine-701 and serine-727 on STAT-1, and did not induce PKR and HSP-70 in OR6 cells GGA mediated phosphorylation of STAT-1 at the tyrosine-701 and serine-727 residues was investigated using antibodies to phospho-specific STAT-1 on OR6 cells. No phosphorylation of tyrosine-701 and serine-727 on STAT-1 was detected in OR6 cells (Fig. 2a) . IFN induce anti-viral protein, PKR, and STAT-1 has an interferon stimulating responsive element (ISRE) in the promoter region [12] . The expression levels of both proteins did not change throughout this study, as indicated by a Western blotting analysis (Fig. 2b, c) . Next, the role of HSP in the mechanism of GGA activity was examined because GGA is an inducer of HSP. The HSP-70 expression was increased by pre-exposure to heat shock (Fig. 2d, lanes 2, 4) , but it did not increase due to the effects of GGA (Fig. 2d, lanes 3, 4) .
Rapamycin and mTOR specific siRNA, but not PI3-K inhibitor and Akt inhibitor, were able to cancel the GGA induced anti-HCV activity
The role of the PI3-K-Akt-mTOR pathway the anti-HCV activity of GGA was examined in OR6 cells. The cells were treated with GGA after 3 h in the presence or absence of rapamycin as an mTOR inhibitor, Akt inhibitor, or wortmannin as a PI3-K inhibitor (Fig. 3) . Pretreatment with rapamycin attenuated the anti-HCV replication effect (Fig. 3, lanes 17-20) , whereas pretreatment with wortmannin and Akt inhibitor did not increase the Renilla luciferase activity (Fig. 3 , lanes 7-10, 12-15). siRNA transfection was used for mTOR knockdown to explore role of mTOR in the anti-HCV activity (Fig. 4) . The transfection efficiency of the siRNA was confirmed by a Western blotting analysis. In this experiment, the detectable band intensities were quantified by the National Institutes of Health image software program. Although the transfection efficiency of siRNA was barely 46% (Fig. 4a) , GGA-induced anti-HCV activity was clearly inhibited in mTOR-siRNA transfected cells (Fig. 4b, lane 4, 6 ) in comparison to the control cells (Fig. 4b, lanes 3, 5) .
GGA induced mTOR activity, mTOR phosphorylation and p70S6K phosphorylation in OR6 cells
The phosphorylation of the serine-2448 residues of mTOR by 50 lmol/L of GGA was detected 30 min after GGA treatment. The band intensity of serine-2448 phosphorylated mTOR decreased by pretreatment with rapamycin but was almost same as with GGA alone following pretreatment with LY294002 (Fig. 5a) . Furthermore, an mTOR activity assay was conducted to confirm the activity mechanism of GGA (Fig. 5b) . The mTOR activity was increased by treatment with GGA alone (Fig. 5b, lane 4) and was inhibited by pretreatment with rapamycin (Fig. 5b , lane 6), whereas pretreatment with LY94002 did not suppress the mTOR activity (Fig. 5b, lane 5) . Furthermore, to evaluate the mTOR activity, we investigated the level of phospholylated-p70S6K by a Western blotting analysis (Fig. 5c ). The phosphorylation of the threonine-389 residue of p70S6K by 50 lmol/L of GGA was detected. Similar to mTOR, the band intensity of phospho-threonine-389 of p70S6K decreased after pretreatment with rapamycin, but the intensity was almost the same as that seen following treatment with GGA alone after pretreatment with LY294002 (Fig. 5c ).
Discussion
GGA demonstrated the anti-HCV activity in this study. The anti-HCV effect depended on the GGA induced mTOR activity, not STAT-1 activity. An additive effect was observed with the combination of IFN and GGA. GGA is a non-toxic heat shock protein (HSP) 70 inducer [13] . Various GGA activities outside of the stomach are also related to HSP induction [14] [15] [16] . GGA induced HSP-70 exerts an anti-ischemic stress activity in the heart and liver [16, 17] , an anti-inflammatory activity in various cell types [18] and promotes liver regeneration [19] . GGA induces thioredoxin as well as HSP-70 in hepatocytes and other cells [20] . Thioredoxin anti-virus activity, is induced by AP-1 and NF-jB but not HSP-70 [21] . GGA has potent 195-202 199 antiviral activity via the enhancement of antiviral factors and can clinically provide protection from influenza virus infection [22] . GGA significantly inhibits the synthesis of influenza virus-associated proteins and prominently enhances the expression of human myxovirus resistance 1 (MxA) followed by increased HSP-70 transcription [22] . Moreover, GGA augments the expression of an interferoninducible double-strand RNA-activated protein kinase (PKR) gene and promotes PKR autophosphorylation and concomitantly alpha subunit of eukaryotic initiation factor 2 phosphorylation during influenza virus infection [22] . These anti-virus activities are related to GGA induced HSP-70. But, HSP-70 protein and PKR were not induced by GGA in OR6 cells in the current study. There is apparently no relationship between the GGA induced anti-HCV activity and HSP, PKR in OR6 cells. Therefore, we thought that HSP and PKR-independent anti-HCV activity induced by GGA was present in this hepatoma-derived cell line. GGA induction of anti-viral protein is dependent upon STAT-1 tyrosine phosphorylation in HuH-7 and HepG2 [10] . However, GGA did not induce STAT-1 tyrosine phosphorylation and anti-virus protein, PKR, in OR6 cells in this study. Moreover, the GGA induced anti-HCV activity depended on mTOR activity, not STAT-1. OR6 cells are full length HCV replicon transfected HuH-7 cells [11] . HCV virus products inhibit the Jak-STAT pathway [23] [24] [25] . The mechanism of inhibition of the Jak-STAT pathway is multi-factorial including the suppressor of cytokine signaling 3 (SOCS-3) expression [26] , protein phosphatase 2A (PP2A) induction [27] , STAT-3 expression [28] and IL-8 expression [29] . GGA induced STAT-1 tyrosine phosphorylation and inducible PKR protein levels are also minor. Generally, the replicon transfection induces the intrinsic IFN [30] , but STAT-1 tyrosine phosphorylation was not detected in combined OR6 cells. HCV replicon produced viral product might be inhibiting GGA-induced STAT-1 tyrosine phosphorylation. mTOR is associated with the IFN induced anti-HCV signal [31] . The IFN activated mTOR pathway exhibits important regulatory effects in the generation of the IFN responses, including the anti-encephalomyocarditis virus effect [32] . IFN-induced mTOR is LY294002 sensitive and does not affect the IFN-stimulated regulatory element (ISRE) dependent promoter gene activity. A relationship has been observed between the replication of the hepatitis virus and mTOR activity. p21-activated kinase 1 is activated through the mTOR/p70 S6 kinase pathway and regulates the replication of HCV [33] . The IFN induced mTOR activity, independent of PI3K and Akt, is the critical factor for its anti-HCV activity and Jak independent TOR activity involves STAT-1 phosphorylation and nuclear localization, and then PKR is expressed in hepatocytes [31] . No relationship between GGA and mTOR has been reported. However, GGA induced anti-HCV activity depended on mTOR activity independent of PI3-K-Akt, as observed with IFN induced mTOR activity.
When 150 mg of GGA was administered orally, the serum concentration of GGA was approximately 7 lmol/L [34] . The concentration of GGA in the portal blood would be several-fold higher than the serum concentration of GGA; therefore, we speculated that the pharmacological action that would be obtained in clinical practice would be the same as that observed in this study.
GGA, a drug that can be safely administered orally, has mTOR dependent anti-HCV activity. The combination of IFN and GGA has an additive effect on anti-HCV activity. The current results suggest that combination therapy with 3 and 5) . One day later, the cells were treated with GGA (lanes 3-6). The HCV replicon assay is the same as Fig. 3 . Non-treatment OR6 cells has 100% of relative Renilla luciferase light unit. The Renilla luciferase activity increased in the OR6 cells transfected with mTOR-siRNA (lane 2) in comparison to the non-targeted siRNA (lane 1). However, in OR6 cells treated with GGA, there was a greater elevation of Renilla luciferase activity in OR6 cells transfected with mTOR-siRNA (lanes 4 and 6) as compared to that with the non-targeted siRNA (lanes 3 and 5) . The data are expressed as the mean ± SD and are representative example of four similar experiments GGA and IFN is, therefore, expected to improve the anti-HCV activity. It will, therefore, be necessary to examine the clinical effectiveness of the combination with GGA and IFN for HCV patients in the future.
